Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 7/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7003368 | 0.80 | MAPK1 (0.39) | GSK3B | |
| SCHEMBL3573567 | 0.74 | MEN1 (0.35) | GSK3B | |
| SCHEMBL3573572 | 0.74 | MEN1 (0.35) | GSK3B | |
| SCHEMBL3573569 | 0.74 | MEN1 (0.35) | GSK3B | |
| SCHEMBL7002558 | 0.69 | GSK3B (0.35) | GSK3B | |
| SCHEMBL3577522 | 0.67 | KDM4E (0.45) | GSK3B | |
| SCHEMBL3566871 | 0.65 | GSK3B (0.49) | GSK3B | |
| SCHEMBL3568873 | 0.65 | GSK3B (0.46) | GSK3B | |
| SCHEMBL3568036 | 0.63 | DPP4 (0.38) | GSK3B | |
| SCHEMBL4872096 | 0.60 | GSK3B (0.38) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340760-A1 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-09-03 | — | — | EP | disclosed |
| EP-1295884-A1 | 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-03-26 | — | — | EP | disclosed |